The Department for Health and Social care has asked NICE to carry out a Single Technology Appraisal of nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer.
However, following an update from the company, NICE has decided to suspend this appraisal on its current work programme.
As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes .
Status | Suspended |
Decision | Selected |
Process | TAG |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
31 May 2018 | Suspended. The Department for Health and Social care has asked NICE to carry out a Single Technology Appraisal of nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer. However, following an update from the company, NICE has decided to suspend this appraisal on its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes . |
27 July 2017 | In progress. In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual